LCC Therapeutics Ltd. is pleased to announce the launch of its new company name, in line with the company transitioning from a CRO to a hub-and-spoke biotechnology company.
LCC was founded in 2014 at the University of Liverpool, with a mission of improving access to novel, chiral chemical space. Following growing success as a fee-for-service business unit, LCC moved to The Heath Business & Technical Park in 2022. The move enabled a laboratory expansion where LCC initially built their Production and Parallel Synthesis Laboratories (PSL), followed by the opening of a second Production lab in 2024.
Combining synthesis-led design and automated/parallel synthesis, LCC developed their proprietary ultra-large virtual chemical library (>1 billion). The library plays an integral role in the company’s PACE™ Platform, which alongside strategic partners with biology-focused platforms, will be used to advance the development of new best-in-class small molecule therapeutics.
LCC has formed their first strategic partnership with Veritas in Silico, in which they are undergoing shared risk projects to discover and develop small molecule therapeutics against mRNA targets and are in discussions with other potential strategic partners.
“The LCC Team and I would like to thank everyone who has supported us along the way in reaching this key milestone. There are too many to name, but thank you to The Heath, who enabled us to expand our laboratory capabilities, which has been a key contributor to our continued growth and success as a company. We look forward to this next part of our journey where we will be applying our PACE™ Platform to accelerate the discovery of high-quality, best-in-class small molecule therapeutics.” – Paul Colbon, CEO & Co-Founder
LABORATORY & OFFICE SPACES AVAILABLE TO LET